Galectin Therapeutics (GALT) News Today $2.15 -0.02 (-0.69%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.15 0.00 (-0.23%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average - Here's What HappenedJuly 1, 2025 | marketbeat.comGalectin Therapeutics Inc. (GALT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street ZenJune 21, 2025 | marketbeat.comGalectin Therapeutics Inc. Common Stock (GALT)June 20, 2025 | nasdaq.comGalectin Therapeutics Inc.June 20, 2025 | wsj.comWhat is HC Wainwright's Estimate for GALT Q2 Earnings?June 19, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT)June 17, 2025 | marketbeat.comGalectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension TreatmentJune 11, 2025 | nasdaq.comGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal HypertensionJune 10, 2025 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business UpdateMay 17, 2025 | seekingalpha.comGalectin Therapeutics (GALT) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comGalectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 CongressMay 12, 2025 | globenewswire.comGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 CongressApril 15, 2025 | markets.businessinsider.comGalectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLCApril 13, 2025 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for GALTApril 8, 2025 | marketbeat.comFY2029 Earnings Forecast for GALT Issued By HC WainwrightApril 6, 2025 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT)April 4, 2025 | marketbeat.comH.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)April 2, 2025 | markets.businessinsider.comGalectin Therapeutics reports FY24 EPS (76c) vs (74c) last yearApril 2, 2025 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPSApril 1, 2025 | marketbeat.comGalectin Therapeutics Reports 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comGalectin Therapeutics (GALT) to Release Quarterly Earnings on FridayMarch 28, 2025 | marketbeat.comWhile insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownershipMarch 8, 2025 | finance.yahoo.comGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE TrialFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics’ belapectin shows reduction in new varicesFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics shareholders elect directors, ratify auditorJanuary 29, 2025 | msn.comInvestors Purchase High Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)January 15, 2025 | marketbeat.comGalectin Therapeutics to Present at the 2025 MASH-TAG ConferenceJanuary 10, 2025 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell"December 30, 2024 | marketbeat.comShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 41.1%December 30, 2024 | marketbeat.comHC Wainwright & Co. Downgrades Galectin Therapeutics (GALT)December 28, 2024 | msn.comGalectin Therapeutics downgraded to Neutral from Buy at H.C. WainwrightDecember 27, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Earns Neutral Rating from HC WainwrightDecember 27, 2024 | marketbeat.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of StockDecember 27, 2024 | insidertrades.comKhurram Jamil Sells 13,654 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) StockDecember 26, 2024 | marketbeat.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells 40,000 Shares of StockDecember 26, 2024 | marketbeat.comGalectin Therapeutics Inc. (NASDAQ:GALT) CEO Sells 56,000 Shares of StockDecember 26, 2024 | marketbeat.comWhy Is Galectin Stock Falling In Pre-market?December 20, 2024 | markets.businessinsider.comGalectin drops as trial for lead asset fails in MASHDecember 20, 2024 | seekingalpha.comGalectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASHDecember 20, 2024 | globenewswire.comStock Traders Purchase Large Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)December 16, 2024 | marketbeat.comAlibaba Stock Rips Higher As China Vows Serious Stimulus, But Is BABA Stock A Buy Now?December 10, 2024 | yahoo.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.comNovember 20, 2024 | marketbeat.comGalectin Therapeutics presents three abstracts at AASLD 2024 Liver MeetingNovember 18, 2024 | markets.businessinsider.comGalectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingNovember 18, 2024 | globenewswire.comHC Wainwright Has Bearish Estimate for GALT FY2027 EarningsNovember 18, 2024 | marketbeat.comOptimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost ProspectsNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics Reports Increased Q3 LossesNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Given "Buy" Rating at HC WainwrightNovember 15, 2024 | marketbeat.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business UpdateNovember 14, 2024 | globenewswire.com Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address GALT Media Mentions By Week GALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼1.050.58▲Average Medical News Sentiment GALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼11▲GALT Articles Average Week Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EOLS News UPB News XNCR News SAGE News KALV News DNTH News RLAY News IOVA News AMLX News DNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GALT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts